Noxxon Pharma

Noxxon Pharma AG
Aktiengesellschaft
Founded 1997
Headquarters Berlin, Germany
Key people
  • Aram Mangasarian, CEO
  • Hubert Birner, Chairman of the supervisory board
Number of employees
 55 (2014)[1]
Website www.noxxon.com

Noxxon Pharma AG is a small-to-medium-sized company founded in year 1997 in Berlin, Germany and since then is headquartered there. The stocks of the company are not publicly traded. Noxxon is a registered trademark[2] and represents a palindrome.

Noxxon Pharma develops drugs under a patented technology yielding L-RNA molecules, which are of mirror-image configuration compared to natural occurring D-RNA molecules. This class of agents is termed Spiegelmer,[3][4] which is a registered trademark of Noxxon Pharma AG.,[5] from Spiegel, the German word for "mirror." The company is member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).

Products

While no Spiegelmer is on the market yet, some candidates are in clinical trials. Drug candidates for different diseases (indications) are evaluated:

In the area of oncology a Spiegelmer is under development for treatment of Multiple myeloma (MM) and Chronic lymphocytic leukemia (CLL).[6][7][8]

A different Spiegelmer is currently being tested for the treatment of a progressive kidney disease in diabetics, Diabetic nephropathy.[9] Favorable results were reported in June, 2014 in a company press release.[10]

A third Spiegelmer is currently in a clinical trial for the treatment of Anemia of chronic disease.[11][12]

References

  1. ↑ Home. Noxxon.com. Retrieved on 2014-12-01.
  2. ↑ DPMAregister
  3. ↑ Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects". Curr Opin Drug Discov Devel. 6 (2): 253–61. PMID 12669461.
  4. ↑ Eulberg D, et al. (2006), 18, "Spiegelmers for Therapeutic Applications" (in German), The Aptamer Handbook (WILEY-VCH): pp. 417-42, ISBN 3-527-31059-2
  5. ↑ DPMAregister
  6. ↑ Vater A, et al. (July 2013). "Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12". Clin Pharmacol Ther. 94 (1): 150–7. doi:10.1038/clpt.2013.58. PMID 23588307.
  7. ↑ Clinical trial number NCT01521533 for "NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma" at ClinicalTrials.gov
  8. ↑ Clinical trial number NCT01486797 for "NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia" at ClinicalTrials.gov
  9. ↑ Clinical trial number NCT01547897 for "NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria" at ClinicalTrials.gov
  10. ↑ http://www.noxxon.com/downloads/pressrel/2014-06-02_NOXXONs_Emapticap_Pegol_Study_Selected_for_Late_Breaking_Clinical_Trials_Symposium.pdf.
  11. ↑ Clinical trial number NCT01691040 for "Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer" at ClinicalTrials.gov
  12. ↑ Schwoebel F, et al. (March 2013). "The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys". Blood. 121 (12): 2311–5. doi:10.1182/blood-2012-09-456756. PMID 23349391.

External links

This article is issued from Wikipedia - version of the 11/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.